Research ArticleArticle
Pharmacokinetics and Pharmacodynamics of the SGLT2 Inhibitor Remogliflozin Etabonate in Subjects with Mild and Moderate Renal Impairment
Robin O’Connor-Semmes, Susan Walker, Anita Kapur, Elizabeth K. Hussey, June Ye, Laurene Wang-Smith, Wenli Tao, Robert L. Dobbins, Bentley Cheatham and William O. Wilkison
Drug Metabolism and Disposition July 2015, 43 (7) 1077-1083; DOI: https://doi.org/10.1124/dmd.114.062828
Robin O’Connor-Semmes
GlaxoSmithKline, Research Triangle Park, North Carolina (R.O.-S., A.K., E.K.H., J.Y., L.W.-S., W.T., R.L.D.); and BHV Pharma, Raleigh, North Carolina (S.W., B.C., W.O.W.)
Susan Walker
GlaxoSmithKline, Research Triangle Park, North Carolina (R.O.-S., A.K., E.K.H., J.Y., L.W.-S., W.T., R.L.D.); and BHV Pharma, Raleigh, North Carolina (S.W., B.C., W.O.W.)
Anita Kapur
GlaxoSmithKline, Research Triangle Park, North Carolina (R.O.-S., A.K., E.K.H., J.Y., L.W.-S., W.T., R.L.D.); and BHV Pharma, Raleigh, North Carolina (S.W., B.C., W.O.W.)
Elizabeth K. Hussey
GlaxoSmithKline, Research Triangle Park, North Carolina (R.O.-S., A.K., E.K.H., J.Y., L.W.-S., W.T., R.L.D.); and BHV Pharma, Raleigh, North Carolina (S.W., B.C., W.O.W.)
June Ye
GlaxoSmithKline, Research Triangle Park, North Carolina (R.O.-S., A.K., E.K.H., J.Y., L.W.-S., W.T., R.L.D.); and BHV Pharma, Raleigh, North Carolina (S.W., B.C., W.O.W.)
Laurene Wang-Smith
GlaxoSmithKline, Research Triangle Park, North Carolina (R.O.-S., A.K., E.K.H., J.Y., L.W.-S., W.T., R.L.D.); and BHV Pharma, Raleigh, North Carolina (S.W., B.C., W.O.W.)
Wenli Tao
GlaxoSmithKline, Research Triangle Park, North Carolina (R.O.-S., A.K., E.K.H., J.Y., L.W.-S., W.T., R.L.D.); and BHV Pharma, Raleigh, North Carolina (S.W., B.C., W.O.W.)
Robert L. Dobbins
GlaxoSmithKline, Research Triangle Park, North Carolina (R.O.-S., A.K., E.K.H., J.Y., L.W.-S., W.T., R.L.D.); and BHV Pharma, Raleigh, North Carolina (S.W., B.C., W.O.W.)
Bentley Cheatham
GlaxoSmithKline, Research Triangle Park, North Carolina (R.O.-S., A.K., E.K.H., J.Y., L.W.-S., W.T., R.L.D.); and BHV Pharma, Raleigh, North Carolina (S.W., B.C., W.O.W.)
William O. Wilkison
GlaxoSmithKline, Research Triangle Park, North Carolina (R.O.-S., A.K., E.K.H., J.Y., L.W.-S., W.T., R.L.D.); and BHV Pharma, Raleigh, North Carolina (S.W., B.C., W.O.W.)
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleArticle
PK and PD of Remogliflozin in Patients with Mild and Moderate Renal Impairment
Robin O’Connor-Semmes, Susan Walker, Anita Kapur, Elizabeth K. Hussey, June Ye, Laurene Wang-Smith, Wenli Tao, Robert L. Dobbins, Bentley Cheatham and William O. Wilkison
Drug Metabolism and Disposition July 1, 2015, 43 (7) 1077-1083; DOI: https://doi.org/10.1124/dmd.114.062828
Research ArticleArticle
PK and PD of Remogliflozin in Patients with Mild and Moderate Renal Impairment
Robin O’Connor-Semmes, Susan Walker, Anita Kapur, Elizabeth K. Hussey, June Ye, Laurene Wang-Smith, Wenli Tao, Robert L. Dobbins, Bentley Cheatham and William O. Wilkison
Drug Metabolism and Disposition July 1, 2015, 43 (7) 1077-1083; DOI: https://doi.org/10.1124/dmd.114.062828
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement